A Study to Find Out if the New Ebola Vaccine is Safe and Stimulates Immunity That Might Protect Adults in Kilifi, Kenya.
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of the BPSC1001 (VSVΔG-ZEBOV) Ebola Virus Vaccine Candidate in Healthy Adult Volunteers in Kilifi, Kenya.
Sponsor: Albert Schweitzer Hospital
This PHASE1 trial investigates Ebola Virus Disease and is currently ongoing. Albert Schweitzer Hospital leads this study, which shows 8 recorded versions since 2014 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Dec 2024 — Present [monthly]
Unknown PHASE1
-
Sep 2024 — Dec 2024 [monthly]
Unknown PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE1
▶ Show 3 earlier versions
-
May 2018 — Jun 2018 [monthly]
Unknown Status PHASE1
Status: Active Not Recruiting → Unknown Status
-
Feb 2017 — May 2018 [monthly]
Active Not Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1
First recorded
Dec 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Albert Schweitzer Hospital
- Institute of Tropical Medicine, University of Tuebingen
- Philipps University Marburg
- University Hospital, Geneva
- University of Oxford
- Universitätsklinikum Hamburg-Eppendorf
- Wellcome Trust
- World Health Organization
For direct contact, visit the study record on ClinicalTrials.gov .